Study of ZG006 in Participants With Small Cell Lung Cancer or Neuroendocrine Carcinoma
A phase 1/2 trial of ZG006 in small-cell lung cancer, run by Suzhou Zelgen Biopharmaceuticals Co.,Ltd, now recruiting.
Overview
Study of ZG006 in Participants With Small Cell Lung Cancer or Neuroendocrine Carcinoma is a phase 1/2 interventional study registered as NCT05978284 by Suzhou Zelgen Biopharmaceuticals Co.,Ltd, with 54 participants planned, started 2023-10-27 and due to reach its primary completion in 2026-09. Interventions recorded: ZG006. Conditions listed: Small Cell Lung Cancer, Neuroendocrine Carcinoma. No results are recorded here; the registry entry is the source.
Similar pages
not linked directly; found by shared links- TrialDose Escalation Study of ZG006 in Participants With Advanced Small Cell Lung Cancer or Neuroendocrine Carcinoma, Followed by Dose Expansion Study in P
Shares ZG006, Suzhou Zelgen Biopharmaceuticals, Small-cell lung cancer.
- TrialZG006 and ZG005 in Participants With Small Cell Lung Cancer or Neuroendocrine Carcinoma
Shares ZG006, Suzhou Zelgen Biopharmaceuticals, Small-cell lung cancer.
- TrialStudy Comparing ZG006 With Investigator-Selected Chemotherapy in Participants With Relapsed Small Cell Lung Cancer
Shares ZG006, Suzhou Zelgen Biopharmaceuticals.
- TrialStudy of ZGGS34 in Participants With Advanced Solid Tumors
Shares ZG006, Suzhou Zelgen Biopharmaceuticals.
- TrialDose Escalation Study of ZG006 in Participants With Advanced Small Cell Lung Cancer or Neuroendocrine Carcinoma, Followed by Dose Expansion Study in Participants With Neuroendocrine Carcinoma.
Shares ZG006, Suzhou Zelgen Biopharmaceuticals.